Imagine if we could spot the exact genetic 'switch' that makes a child prone to obesity before it happens. This project looks at DNA and lifestyle data to find these triggers and test targeted treatments. It's like finding the root of a weed in a garden so it never grows into a giant problem for the adult plant.
Adult obesity is difficult to treat, and childhood obesity rates have surged to 32% in Europe. There is a lack of precision tools to predict and prevent this transition at a molecular level.
The project is building a European catalogue of longitudinal cohorts, proprietary predictive tools for obesity, and a clinical study protocol for GLP1R agonists.
If you are a drug development firm dealing with the need for new metabolic targets — this project developed a method to identify at least 3 novel childhood obesity genes that can be used to find new drug targets.
If you are a genetic testing laboratory dealing with imprecise obesity screening — this project developed early predictive proprietary tools and whole-exome sequencing workflows that allow for precision medicine for children with pathogenic mutations.
If you are a health-tech app developer dealing with low user engagement in obesity prevention — this project developed a participative medicine model involving families, schools, and municipalities to improve the success of interventions.
Based on available project data, specific pricing for the proprietary tools is not provided, though the project received a total EU contribution of EUR 10,054,268 for development.
The project is currently in the research and clinical study phase, focusing on identifying genes and testing drugs like GLP1R agonists, meaning it is not yet at industrial scale.
The project aims to develop proprietary tools for prediction and treatment; however, specific licensing terms are not detailed in the provided data.
The project period runs from 2023-05-01 to 2028-04-30, with results expected by the end of this window.
The project translates clinical results into guidelines and proposals for policy makers to change obesity care across Europe.
The consortium is heavily weighted toward research and academia, with 8 universities and 6 research institutes. However, there is a strategic industrial presence with 2 industry partners (11% ratio), including one SME, indicating a bridge between molecular discovery and commercial application across 10 countries.
Contact the Institut National de la Santé et de la Recherche Médicale (INSERM) in France.
Contact us to explore licensing opportunities for the predictive obesity tools.
